Overview

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

Status:
Not yet recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia
Phase:
Phase 2
Details
Lead Sponsor:
Technoderma Medicines Inc.
Collaborator:
Therapeutics, Inc.